Sojournix Inc.
https://www.sojournixpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sojournix Inc.
Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.
Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.
Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna
Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice